PD-1/PD-L1 与胰腺癌的免疫治疗。
PD-1/PD-L1 and immunotherapy for pancreatic cancer.
机构信息
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China; Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
出版信息
Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18.
Therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1), which are known as immune checkpoints, has been recently rapidly developing as oncotherapy for various carcinomas. However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy. In this review, the development and limitations of anti-PD-1/PD-L1 monotherapy in pancreatic cancer are discussed. We then consider the underlying mechanism of anti-PD-1/PD-L1 monotherapy failure, combination strategies overcoming resistance to anti-PD-1/PD-L1 immunotherapy and the prospect of targeting PD-1/PD-L1 for the immunotherapy of pancreatic cancer.
针对程序性死亡受体 1 或程序性死亡受体配体 1（PD-1/PD-L1）的治疗方法，也就是免疫检查点，最近作为各种癌症的肿瘤治疗方法迅速发展。然而，这种疗法对 PD-1/PD-L1 单药阻断治疗胰腺癌的效果较差。在这篇综述中，讨论了抗 PD-1/PD-L1 单药治疗在胰腺癌中的发展和局限性。然后，我们考虑了抗 PD-1/PD-L1 单药治疗失败的潜在机制、克服抗 PD-1/PD-L1 免疫治疗耐药的联合策略，以及针对 PD-1/PD-L1 进行胰腺癌免疫治疗的前景。
Zotero 插件